SUMMARY Thromboembolism complicates the course of patients with rheumatic heart disease (mitral stenosis) and platelet survival time has been shown to be shortened in patients with a history of thromboembolism; sulfinpyrazone has been shown to increase platelet survival in these patients. A prospective, blinded trial of sulfinpyrazone therapy in patients with rheumatic heart disease has been completed. One hundred fiftyfour of 186 patients had shortened platelet survival (chromium-51 labeling of autologous platelets) on enrollment and were randomized to treatment with either sulfinpyrazone or placebo. Thirty-two patients with initially normal platelet survival were neither randomized nor treated. New thromboembolism occurred in 19 patients during 4 years of observation: two received sulfinpyrazone, 16 received placebo (X2 = 12.75,p < 0.01) and one had normal initial platelet survival time. Sulfinpyrazone increased platelet survival time (control 2.5 ± 0.04 days [average ± SEMI; normal half life 3.7 ± 0.03 days; 1 year 2.8 ± 0.04 days; n = 78) relative to placebo (control 2.6 ± 0.04 days; 1 year 2.5 ± 0.05 days; n = 76, p < 0.01). The results of this trial confirm earlier work suggesting that platelet survival time is frequently shortened in patients with rheumatic heart disease, and that sulfinpyrazone increases platelet survival. Sulfinpyrazone appears to decrease thromboembolism in patients with rheumatic mitral stenosis.
THROMBOEMBOLISM frequently occurs in patients with rheumatic heart disease.1 2 Although anticoagulants appear to be effective in preventing embolism in these patients, these drugs are associated with a definite risk of bleeding and are inconvenient for the patient to take. A role for platelets in the pathogenesis of thromboembolism in these patients was suggested by the frequent occurrence of shortened platelet survival time, particularly in patients with a history of thromboembolism.3 The platelet-suppressant drug sulfinpyrazone increases platelet survival time in patients with rheumatic heart disease.3 We undertook a prospective clinical trial to determine the value of treating rheumatic heart disease patients with sulfinpyrazone and measuring platelet survival time.
Patients
Patients with clinical evidence of rheumatic heart disease (mitral stenosis) underwent measurement of platelet survival time and those with shortened platelet survival were randomized to treatment (double blind) with either sulfinpyrazone (200 mg orally four times daily) or placebo. Patients whose initial platelet survival time was normal were not randomized and were not treated. All patients had the characteristic auscultatory findings of mitral stenosis and most had undergone cardiac catheterization and echocardiography.
All patients with rheumatic heart disease encountered by the authors were asked to participate in this study, except those certain to undergo mitral or aortic valve replacement surgery within the next year or patients with another serious illness. Patients were excluded if they had clinical evidence of coronary, cerebral or peripheral vascular disease or arterial hypertension. Patients enrolled in the study would be asked to come to Denver for study once a year for 4 years. Twenty-three patients (14 men) declined to participate after discussing the study with the authors. Eight declined because they planned to move from the Rocky Mountain region and another five thought it would be difficult for them to come to Denver for study. Three patients were advised by their physician not to participate and six could not accept randomization. One patient may have had an allergic reaction to sulfinpyrazone. Of the 23 who did not participate, one had a history of embolism (the patient with the allergic reaction).
Diagnostic and therapeutic decisions (e.g., cardiac catheterization, warfarin administration, mitral valve surgery) regarding rheumatic heart disease were not made by the physicians directly involved in the trial. The risks, benefits and design of the trial were explained to all patients and their consent to participate was obtained. Anticoagulation with warfarin was frequently undertaken in these patients during the trial (table 2) . The decision to use warfarin anticoagulation was made by the patient's primary physician. Warfarin did not appear to decrease the risk of new embolism in these patients. Nine of the 19 patients with new embolism had been treated with warfarin for at least 6 months before embolism and 10 had not been treated. In the sulfinpyrazone-treated patients one (of two) was receiving warfarin and the single patient with initially normal platelet survival was not anticoagulated. Eight of the placebo patients who had thromboembolism were anticoagulated with warfarin. Prothrombin times were at least twice control in all anticoagulated patients with embolism. Prothrombin times were repetitively measured between 3 and 6 weeks in all anticoagulated patients. Medication compliance was monitored by supplying each patient with a 3-month supply of medication and by counting capsules. In addition, serum uric acid was measured yearly during measurement of platelet survival time.
Methods
Discussion The results of this study suggest that sulfinpyrazone decreases the frequency of occurrence of systemic embolism in patients with rheumatic heart disease. In the present study embolism occurred in two of 78 patients treated with sulfinpyrazone and in 16 of 76 patients treated with placebo during 4 years of observation. Sulfinpyrazone was well tolerated in these patients and did not appear to alter the natural history of rheumatic heart disease unfavorably.
The results further suggest that platelets contribute to the pathogenesis of thromboembolism in patients with rheumatic heart disease. Platelet survival time appears to be a sensitive index of past systemic embolism in patients with rheumatic heart disease. Shortened platelet survival time was observed in 47 of 48 patients (98%) who had a history of systemic embolism before entry in this trial. Platelet survival time appears to predict embolism, as 18 of 19 patients (95%) who developed embolism during the study had shortened platelet survival time. Sulfinpyrazone increased platelet survival time in these patients and has also been shown to decrease thromboembolism in uremic patients with external arteriovenous shunts' and in patients with recurrent venous thrombosis.6
The cause of shortened platelet survival in patients with rheumatic heart disease is unclear but may be due to increased interaction of platelets with the damaged left atrial endothelial surface. Histologic study of the left atria of patients with rheumatic heart disease has revealed thrombi containing platelets in association with scar-like hyaline connective tissue.7 Fibrinogen survival studies were not performed in the patients in this study, and thus, quantitative data regarding the rate of fibrin deposition are lacking. Selective consumption of platelets is suggested, however, by the effect of sulfinpyrazone and the lack of effect of warfarin on shortened platelet survival. Twelve patients with rheumatic heart disease and shortened platelet survival time were studied after completion of 4 years in this trial while taking warfarin and again 3 months after discontinuing warfarin. The average platelet survival time did not change, and no patient had a change of greater than 0.2 days. In patients with active venous thrombosis, Harker and Slichter8 observed decreased survival of both platelets and fibrinogen. In these patients heparin increased both platelet and fibrinogen survival but the platelet-suppressant drug dipyridamole had no effect.8 The results in rheumatic heart disease suggest selective consumption of platelets similar to results obtained in patients with arterial thrombosis" and prosthetic cardiac valves.9
Although platelet survival time is shortened in patients with rheumatic heart disease who have a history of embolism and who develop embolism, this measurement is not specific for thromboembolism. On entry in the present study, 138 patients did not have a history of thromboembolism and 107 (78%) had shortened platelet survival time. During 4 years of observation, two patients with prior embolism had recurrence and 17 patients had their first embolic episode. The two with recurrence had shortened platelet survival and 16 of 17 with their first embolic episode had shortened platelet survival. Thus, the risk of embolism is associated with shortened platelet survival, but this abnormality is very commonly observed in patients with rheumatic heart disease.
